dacomitinib

Known as: (2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide 
A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
0102020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with… (More)
Is this relevant?
2015
2015
BACKGROUND HER2 mutations and amplifications have been identified as oncogenic drivers in lung cancers. Dacomitinib, an… (More)
Is this relevant?
2015
2015
PURPOSE The goals of this study were to investigate the clinical activity, safety, and biomarkers of dacomitinib, an irreversible… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2015
2015
Glioblastomas (GBM) are devastating tumors in which there has been little clinical improvement in the last decades. New… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
BACKGROUND This phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free survival of 9-13 months while… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in… (More)
  • table 1
  • figure 2
  • figure 3
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth… (More)
Is this relevant?
2012
2012
The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Background Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?